The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia

(2010) R. T. Swords et al.   BLOOD

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

(2010) Agathoclis Agathocleous et al.   BRITISH JOURNAL OF HAEMATOLOGY

Current and emerging therapies for acute myeloid leukemia

(2010) Tadeusz Robak et al.   CLINICAL THERAPEUTICS

Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with the proteasome status

(2009) Mariette Matondo et al.   LEUKEMIA RESEARCH

Antitumor Activity of Bortezomib Alone and in Combination with Trail in Human Acute Myeloid Leukemia

(2008) Concetta Conticello et al.   ACTA HAEMATOLOGICA

Nuclear factor-κB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia

(2008) Christopher Jenkins et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia

(2008) E. C. Attar et al.   CLINICAL CANCER RESEARCH

The potential of proteasome inhibitors in cancer therapy

(2008) Jan Sterz et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

(2008) E. Colado et al.   HAEMATOLOGICA

Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: A gene expression profiling study with implications for potential combination therapies

(2007) Xiaoxian Zhao et al.   LEUKEMIA RESEARCH